Pluristem Therapeutics Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Pluristem Therapeutics Inc. on January 20, 2017, reporting events occurring on January 19 and January 20, 2017. The filing details the entry into a material definitive agreement regarding a public offering of common stock and warrants.
Key Financial Metrics and Transaction Details
- Offering Size: The company entered into an amended underwriting agreement to sell 12,244,898 shares of common stock and warrants to purchase 7,346,939 shares of common stock.
- Expected Net Proceeds: Approximately $13,725,000, assuming no exercise of the over-allotment option or warrants.
- Underwriting Fees: A cash commission of 6% of aggregate gross proceeds plus coverage of other expenses.
- Warrant Terms: Exercise price of $1.40 per share; exercisable for 5.5 years commencing six months after issuance.
- Over-Allotment Option: The underwriter holds a 30-day option to purchase up to 1,836,735 additional shares and/or warrants to cover over-allotments.
- Closing Date: Expected on January 25, 2017, subject to customary conditions.
Note: This filing does not provide historical revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on the capital raise transaction.
Material Changes
The primary material change is the amendment of the initial underwriting agreement on January 20, 2017. The offering size was increased from the initial 8,163,265 shares and 4,897,959 warrants to 12,244,898 shares and 7,346,939 warrants.
Outlook, Risks, and Contingencies
- Contingency: The transaction is subject to the satisfaction of customary closing conditions.
- Market Risk: The warrants will not be listed on the NASDAQ Capital Market or any other exchange, and no trading market for the warrants is expected to develop.
- Regulatory Status: The offering is made pursuant to a shelf registration statement (Form S-3) declared effective on October 30, 2014.
Key Facts for Investor Verification
- Verify the final closing of the offering on or around January 25, 2017.
- Confirm whether the underwriter exercises the 30-day over-allotment option.
- Review the full Amended and Restated Underwriting Agreement (Exhibit 1.2) for specific covenants and conditions.
- Monitor the company's cash position post-closing to assess the impact of the $13.7 million net proceeds on liquidity.